121 related articles for article (PubMed ID: 1574922)
1. Use of low toxicity adjuvants and killed virus to induce protective immunity against the Friend murine leukaemia retrovirus-induced disease.
Ishihara C; Miyazawa M; Nishio J; Azuma I; Chesebro B
Vaccine; 1992; 10(5):353-6. PubMed ID: 1574922
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine.
Yoo YC; Yoshimatsu K; Koike Y; Hatsuse R; Yamanishi K; Tanishita O; Arikawa J; Azuma I
Vaccine; 1998; 16(2-3):216-24. PubMed ID: 9607033
[TBL] [Abstract][Full Text] [Related]
3. Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene.
Miyazawa M; Nishio J; Chesebro B
J Virol; 1992 Jul; 66(7):4497-507. PubMed ID: 1534853
[TBL] [Abstract][Full Text] [Related]
4. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant.
Earl PL; Moss B; Morrison RP; Wehrly K; Nishio J; Chesebro B
Science; 1986 Nov; 234(4777):728-31. PubMed ID: 3490689
[TBL] [Abstract][Full Text] [Related]
5. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development.
Miyazawa M; Fujisawa R; Ishihara C; Takei YA; Shimizu T; Uenishi H; Yamagishi H; Kuribayashi K
J Immunol; 1995 Jul; 155(2):748-58. PubMed ID: 7541823
[TBL] [Abstract][Full Text] [Related]
7. Interference of retroviral envelope with vaccine-induced CD8
Bongard N; Lapuente D; Windmann S; Dittmer U; Tenbusch M; Bayer W
Retrovirology; 2017 Apr; 14(1):28. PubMed ID: 28449719
[TBL] [Abstract][Full Text] [Related]
8. Induction of protective immunity to Friend murine leukemia virus in genetic nonresponders to virus envelope protein.
Ishihara C; Miyazawa M; Nishio J; Chesebro B
J Immunol; 1991 Jun; 146(11):3958-63. PubMed ID: 2033265
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
[TBL] [Abstract][Full Text] [Related]
10. Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen. Identification of class II loci of the H-2 as immune response genes.
Miyazawa M; Nishio J; Chesebro B
J Exp Med; 1988 Nov; 168(5):1587-605. PubMed ID: 3141552
[TBL] [Abstract][Full Text] [Related]
11. Identification of a protective CD4+ T-cell epitope in p15gag of Friend murine leukemia virus and role of the MA protein targeting the plasma membrane in immunogenicity.
Sugahara D; Tsuji-Kawahara S; Miyazawa M
J Virol; 2004 Jun; 78(12):6322-34. PubMed ID: 15163726
[TBL] [Abstract][Full Text] [Related]
12. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
[TBL] [Abstract][Full Text] [Related]
13. Immunoprevention of Friend leukaemia virus-induced erythroleukaemia by vaccination with aggregated gp70.
Kleiser C; Schneider J; Bayer H; Hunsmann G
J Gen Virol; 1986 Sep; 67 ( Pt 9)():1901-7. PubMed ID: 2427646
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
[TBL] [Abstract][Full Text] [Related]
15. Synthetic vaccines against Friend murine leukaemia virus-induced erythroleukaemia: in vivo and in vitro studies with synthetic oligopeptides and sequence-specific antisera.
Bayer H; Hunsmann G
J Gen Virol; 1987 Feb; 68 ( Pt 2)():515-22. PubMed ID: 3469323
[TBL] [Abstract][Full Text] [Related]
16. Approach to a retrovirus vaccine: immunization of mice against Friend virus disease with a replication-defective Friend murine leukemia virus.
Ruan KS; Lilly F
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):12202-6. PubMed ID: 1465459
[TBL] [Abstract][Full Text] [Related]
17. Immunoprotective determinants in friend murine leukemia virus envelope protein.
Hasenkrug KJ; Brooks DM; Robertson MN; Srinivas RV; Chesebro B
Virology; 1998 Aug; 248(1):66-73. PubMed ID: 9705256
[TBL] [Abstract][Full Text] [Related]
18. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms.
Dittmer U; Brooks DM; Hasenkrug KJ
J Virol; 1998 Aug; 72(8):6554-8. PubMed ID: 9658099
[TBL] [Abstract][Full Text] [Related]
20. Different H-2 subregions influence immunization against retrovirus and immunosuppression.
Morrison RP; Earl PL; Nishio J; Lodmell DL; Moss B; Chesebro B
Nature; 1987 Oct 22-28; 329(6141):729-32. PubMed ID: 2823142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
